Serum Interleukin-24 Levels in Gastric and Breast Cancers and Non-cancerous Inflammations

IF 0.4 Q4 ONCOLOGY
M. Khoshroo, M. Yazdanpanah, S. Yasrebi
{"title":"Serum Interleukin-24 Levels in Gastric and Breast Cancers and Non-cancerous Inflammations","authors":"M. Khoshroo, M. Yazdanpanah, S. Yasrebi","doi":"10.30476/MEJC.2020.82945.1122","DOIUrl":null,"url":null,"abstract":"Background: Human interleukin-24 (IL-24) is a cytokine belonging to the interleukin-10 (IL-10) family of cytokines, also known as melanoma differentiation-associated gene 7, due to its discovery as a tumor-suppressing protein. A tumor-suppressing protein, IL-24 is produced by a variety of cells, including cancerous and non-cancerous healthy cells. The aim of the present study was to evaluate serum IL-24 concentrations in different cancers and compare them with non-cancerous inflammations. \nMethod: In this case-control study, we divided a total of 200 subjects into five groups of 40 control subjects without cancer and without Helicobacter Pylori (H. Pylori) infection, patients with gastric cancer and H. Pylori infection, patients with H. Pylori infection without cancer, and patients with breast cancer and without H. Pylori infection. We measured the serum IL-24 level using specific enzyme-linked immunosorbent assay (ELISA) kit; we analysed the data with SPSS software. \nResults: The level of IL-24 was significantly higher in breast cancer group (160.65±55pg/mL) (mean± SD) followed by gastric cancer with (76.2±16.27 pg/mL) (mean±SD) and without (72.5±17.84 pg/mL) (mean± SD) H. Pylori infection groups. The level of IL-24 in H. Pylori infected patients and controls were (32.78±12.96 pg/mL) (mean±SD) and (27.4±8.5 pg/mL (mean±SD)), respectively. \nConclusion: The mechanisms by which IL-24 is produced may be different between immune and cancer cells and serum IL-24 is more likely generated by immune cells than tumor cells. In breast cancer patients, estrogen or other sex hormones may provoke IL-24 production.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":"12 1","pages":"183-189"},"PeriodicalIF":0.4000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2020.82945.1122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Human interleukin-24 (IL-24) is a cytokine belonging to the interleukin-10 (IL-10) family of cytokines, also known as melanoma differentiation-associated gene 7, due to its discovery as a tumor-suppressing protein. A tumor-suppressing protein, IL-24 is produced by a variety of cells, including cancerous and non-cancerous healthy cells. The aim of the present study was to evaluate serum IL-24 concentrations in different cancers and compare them with non-cancerous inflammations. Method: In this case-control study, we divided a total of 200 subjects into five groups of 40 control subjects without cancer and without Helicobacter Pylori (H. Pylori) infection, patients with gastric cancer and H. Pylori infection, patients with H. Pylori infection without cancer, and patients with breast cancer and without H. Pylori infection. We measured the serum IL-24 level using specific enzyme-linked immunosorbent assay (ELISA) kit; we analysed the data with SPSS software. Results: The level of IL-24 was significantly higher in breast cancer group (160.65±55pg/mL) (mean± SD) followed by gastric cancer with (76.2±16.27 pg/mL) (mean±SD) and without (72.5±17.84 pg/mL) (mean± SD) H. Pylori infection groups. The level of IL-24 in H. Pylori infected patients and controls were (32.78±12.96 pg/mL) (mean±SD) and (27.4±8.5 pg/mL (mean±SD)), respectively. Conclusion: The mechanisms by which IL-24 is produced may be different between immune and cancer cells and serum IL-24 is more likely generated by immune cells than tumor cells. In breast cancer patients, estrogen or other sex hormones may provoke IL-24 production.
血清白细胞介素-24在胃癌、乳腺癌和非癌性炎症中的水平
背景:人类白细胞介素-24 (IL-24)是一种属于白细胞介素-10 (IL-10)细胞因子家族的细胞因子,因其作为肿瘤抑制蛋白而被发现,也被称为黑色素瘤分化相关基因7。IL-24是一种肿瘤抑制蛋白,由多种细胞产生,包括癌变和非癌变的健康细胞。本研究的目的是评估不同癌症的血清IL-24浓度,并将其与非癌性炎症进行比较。方法:本病例-对照研究共200例,将患者分为5组,每组40例为无癌且无幽门螺杆菌感染的对照组、胃癌合并幽门螺杆菌感染的对照组、无癌且有幽门螺杆菌感染的对照组、无癌且有幽门螺杆菌感染的对照组和无幽门螺杆菌感染的乳腺癌患者。采用特异性酶联免疫吸附测定(ELISA)试剂盒检测血清IL-24水平;用SPSS软件对数据进行分析。结果:IL-24水平在乳腺癌组显著升高(160.65±55pg/mL)(平均±SD),其次为胃癌组(76.2±16.27 pg/mL)(平均±SD)和未感染幽门螺杆菌组(72.5±17.84 pg/mL)(平均±SD)。幽门螺杆菌感染患者和对照组IL-24水平分别为(32.78±12.96 pg/mL)(平均±SD)和(27.4±8.5 pg/mL(平均±SD))。结论:免疫细胞和肿瘤细胞产生IL-24的机制可能不同,血清IL-24更可能由免疫细胞而非肿瘤细胞产生。在乳腺癌患者中,雌激素或其他性激素可能会刺激IL-24的产生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信